Vitiligo and soft tissue markets projected sales for Recell entirely dwarf that of burns.
Commercial launch for both is 2023 sooner than previously thought:
“Our recent successes in getting two pivotal clinical trials fully enrolled, and also demonstrating proof of concept in two other potential indications, underscore our commitment to further growing the market opportunities for the RECELL system,” said Dr. Mike Perry, AVITA Medical Chief Executive Officer. “Looking ahead, we will be preparing our vitiligo and soft tissue dossiers to submit PMA supplement applications to the FDA in late 2022 for commercial launches for those indications in
With large amounts of cash in the bank and no debt, owning their manufacturing and very high profit margin on RECELL units this company has been currently entirely overlooked by the market. 2023”
We already know it works for vitiligo and soft tissue and given the extensive safety data accumulated its expansion of its label by the FDA will happen (note expansion, not new submission)
No debt. Large amount of cash on hand. Own manufacturing and high margins per RECELL unit sold. Just announced revenue increasing 35percent for dec 2021 qtr 6.9million.
To me RECELL sales to conservatively surpass current MC of 400million within 5 years (3 years from vitiligo and soft tissue launch).
Would conservatively suggest in excess of 3 billion Market Cap by then.
Market has completely overlooked this for now but it will at some point realise.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)